MedPath

Base Therapeutics (Shanghai) Co., Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:0

Trial Phases

1 Phases

Early Phase 1:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Early Phase 1
5 (100.0%)

Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

Early Phase 1
Recruiting
Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
First Posted Date
2024-08-07
Last Posted Date
2024-08-07
Lead Sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Target Recruit Count
9
Registration Number
NCT06541444
Locations
🇨🇳

Shanghai Pudong Hospital, Shanghai, Shanghai, China

Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

Early Phase 1
Recruiting
Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
First Posted Date
2024-08-07
Last Posted Date
2024-08-07
Lead Sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Target Recruit Count
9
Registration Number
NCT06541405
Locations
🇨🇳

Shanghai Children's Medical Center, Shanghai, Shanghai, China

Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

Early Phase 1
Recruiting
Conditions
Osteosarcoma
Soft Tissue Sarcoma
Interventions
First Posted Date
2023-11-07
Last Posted Date
2023-11-07
Lead Sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Target Recruit Count
12
Registration Number
NCT06117878
Locations
🇨🇳

Shanghai General Hospital, Shanghai, China

Safety and Efficacy of NK510 to Treat Gastric Cancer

Early Phase 1
Conditions
Gastric Cancer
Interventions
First Posted Date
2023-10-25
Last Posted Date
2023-10-25
Lead Sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Target Recruit Count
9
Registration Number
NCT06098898
Locations
🇨🇳

Shanghai Tenth People's Hospital, Shanghai, China

Safety and Efficacy of NK510 to Treat NSCLC

Early Phase 1
Recruiting
Conditions
NSCLC
Interventions
First Posted Date
2023-10-24
Last Posted Date
2023-10-25
Lead Sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Target Recruit Count
9
Registration Number
NCT06097962
Locations
🇨🇳

General Hospital of Eastern Theater Command, Nanjing, Jiangsu, China

News

No news found
© Copyright 2025. All Rights Reserved by MedPath